SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novartis AG’s Tasigna Surpasses Glivec In Leukemia Treatment

June 4, 2010 | 
1 min read
ZURICH, June 4 (Reuters) - Swiss drug-maker Novartis (NOVN.VX) said 18-month results from a study confirmed its Tasigna cancer drug is more efficient in slowing down chronic myeloid leukaemia (CLM) than older medicine Glivec.
Clinical research Phase 3
Novartis
MORE ON THIS TOPIC
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Sorting garbage concept. Cropped photo of paper thash. Crumple paper falling to the recycling bin
Drug Development
Genmab drops 2 antibody assets, including another ProfoundBio ADC
May 15, 2026
 · 
2 min read
 · 
Gabrielle Masson
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
 · 
3 min read
 · 
Annalee Armstrong
A vibrant geometric pattern of colorful book spines arranged neatly on shelves. This texture represents organized knowledge and information storage. The minimalist composition and bright colors are ideal for educational, corporate, or creative graphic design projects.
Insights
GPCRs, radiopharma and the rise of functional peptide screening
May 14, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker